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Abstract  51 
 52 
Background: Enterococcal endocarditis (EE) is a growing entity in Western countries. 53 
However, quality data from large studies is lacking.  54 
Objectives: To describe the characteristics and analyze the prognostic factors of EE in the 55 
GAMES cohort. 56 
Methods: Post-hoc analysis of a prospectively collected cohort of patients from 35 Spanish 57 
centers from 2008 to 2016. Characteristics and outcomes of 516 cases of EE were compared 58 
to those of 3,308 cases of non-enterococcal endocarditis (NEE). Logistic regression and Cox 59 
proportional hazards regression analysis were performed to investigate risk factors for in-hospital and 60 
one-year mortality, and relapses.  61 
Results: Patients with EE were significantly older, presented more frequently chronic lung 62 
disease, chronic heart failure, prior endocarditis, degenerative valve disease and had higher 63 
median age-adjusted Charlson score. EE more frequently involved the aortic valve and 64 
prosthesis (64.3% vs. 46.7%; P<0.001; and 35.9% vs. 28.9%; P=0.002, respectively) but less 65 
frequently pacemakers/defibrillators (1.5% vs. 10.5%; P<0.001), and showed higher rates of 66 
acute heart failure (45% vs. 38.3%;P=0.005). Cardiac surgery was less frequently performed 67 
in EE (40.7% vs.45.9%;P=0.024). No differences in in-hospital mortality and one-year 68 
mortality were found, whereas relapses were significantly higher in EE (3.5% vs. 1.7%; 69 
P=0.035). Increasing Charlson score, LogEuroSCORE, acute heart failure, septic shock and 70 
paravalvular complications were risk factors for mortality, whereas prior endocarditis was 71 
protective and persistent bacteremia constituted the sole risk factor for relapse. 72 
Conclusions: Besides other baseline and clinical differences, EE more frequently affects 73 
prosthetic valves and less frequently pacemakers/defibrillators. EE presents higher rates of 74 
relapse than NEE.  75 
 76 
Condensed abstract: Enterococcal endocarditis (EE) is a growing issue in Western 77 
countries. By comparing 516 cases of EE with 3,308 cases of NEE, we found older median 78 
age and higher comorbidity rates among EE than in NEE, as well as higher rates of aortic 79 
valve and prosthetic valve involvement, and heart failure. Mortality did not significantly 80 
differ between EE and NEE, whereas relapses were higher in EE. Risk factors for mortality in 81 
EE were Charlson score, LogEuroSCORE, acute heart failure, septic shock and paravalvular 82 
complications, whereas persistent bacteremia was associated with a higher likelihood of 83 
relapses.  84 
 85 
Keywords: Infective endocarditis, enterococci, heart failure, relapses, prosthetic valves, 86 
epidemiology.  87 
 88 
Abbreviations: CNS, central nervous system; EE, enterococcal endocarditis; HCA, 89 
healthcare-associated; IE, infective endocarditis; MRSA, methicillin-resistant S. aureus; 90 
NEE, non-enterococcal endocarditis; PCM/DF, pacemakers/defibrillators; TAVI, transaortic 91 




Enterococci have been identified as a growing pathogen, primarily in health-care associated 94 
infections in the U.S., where vancomycin-resistant strains pose a serious challenge to the 95 
health system [1]. However, enterococci are also playing an increasingly important role in 96 
infective endocarditis (IE) [2], with most recent series placing it as the third leading causative 97 
agent in high-income countries, reaching up to 15-20% of total cases [3-6]. Moreover, 98 
enterococci are the leading causative agent of transaortic valve implants (TAVI)-associated 99 
IE [7]. 100 
Most cases (around 90%) of enterococcal IE are caused by E. faecalis [8]. Since the turn of 101 
the 21
st
 century, the classically described clinical presentation of enterococcal IE as a 102 
community-acquired, subacute pauci-symptomatic disease of genitourinary source [10] is 103 
progressively turning in a more aggressive, acute, more frequently healthcare-associated 104 
(HCA) disease of occurring predominantly amongst elderly patients with a large burden of 105 
comorbidities and seldom a clear identifiable source. [9,10].  106 
The focus of recent relevant studies addressing enterococcal IE is largely placed on the 107 
genetic and molecular aspects [11,12], impact of antimicrobial resistance (e.g. vancomycin, 108 
high-level aminoglycoside resistance and daptomycin resistance) [1,8,11,12], therapeutic 109 
options [13-15] or the use of TEE to detect IE [16-18], whereas there is a relative paucity of 110 
studies explaining the main clinical and epidemiological changes of enterococcal IE in the 111 
last two decades and their underlying mechanisms, such as its potential association with 112 
colorectal neoplasms [19,20].  113 
We aimed to investigate the main characteristics of enterococcal IE in a cohort of 516 114 
patients prospectively collected from 2008 to 2016 and to compare them with those of non-115 




Design: multicenter prospective observational study including 35 Spanish centers between 118 
2008 and 2016. The characteristics of the GAMES cohort, collection of data variables 119 
through a specific central registration depository, and definitions are described elsewhere [5]. 120 
The work-up for searching potential sources of the infection, including gastrointestinal tract 121 
screening, was not systematic but was decided by the treating physician. Persistent 122 
bacteremia was defined as positive blood cultures beyond seven days of effective antibiotic 123 
therapy; relapse refers to a new episode of IE due to the same microorganism within the next 124 
6 months after the initial episode; acute renal failure was defined in the data collection sheet 125 
as a worsening equal or higher than 25% of serum creatinine or glomerular clearance 126 
occurring within a lapse of 72h; community-acquired IE was defined as IE diagnosed within 127 
the first 48 hours of admission in a patient who did not fulfill the criteria for HCA infection. 128 
HCA infection encompasses nosocomial and non-nosocomial HCA IE [21]. Nosocomial IE 129 
was defined as IE in a patient who had been hospitalized for >48 hours before the onset of 130 
signs or symptoms consistent with IE. Non-nosocomial HCA IE was an IE diagnosed within 131 
48 hours of admission of an outpatient. 132 
Patients: adult individuals with definite or possible IE diagnosed according to the modified 133 
Duke criteria [22].  134 
Outcomes: in-hospital and one-year mortality (death due to any causes within 30 days and 135 
365 days from the admission, respectively), and relapses.  136 
Statistical analysis: Categorical variables were summarized as percentages and continuous 137 
variables as means and standard deviations. Categorical variables were compared using the 138 
chi-square test (or Fisher’s exact test where necessary). Continuous variables were compared 139 
using the Kruskal-Wallis test. Cox proportional hazards regression analysis was utilized to 140 
investigate risk factors for one-year mortality and relapses. Variables with P<0.20 in the 141 
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univariate analysis were included in the models. Kaplan-Meier survival curves free of 142 
mortality at one year and relapses were generated with log-rank test analysis and considering 143 
censored episodes according to the time measured for each endpoint. A two-sided P<0.05 144 
was considered to be statistically significant. Statistical analyses were performed using SPSS 145 
for Windows, Version 16.0 (SPSS Inc, Chicago, Illinois, USA). 146 




Patients with enterococcal IE were significantly older and had higher rates of comorbidities, 149 
leading to a significantly higher median age-adjusted Charlson score (Table 1). Diabetes 150 
mellitus, chronic lung disease, congestive heart failure, previous IE, and non-congenital valve 151 
disease were all significantly more frequent among enterococcal IE, whereas ischemic 152 
cardiomyopathy and chronic renal failure, although more frequent too among enterococcal 153 
IE, did not reach statistical significance. On the other hand, iv drug use, HIV infection and 154 
congenital heart abnormalities were significantly more common among patients with non-155 
enterococcal IE. The proportion of prosthetic valve IE was significantly higher in the 156 
enterococcal IE group, whereas PCM/DF-associated IE was significantly more frequent in the 157 
non-enterococcal IE group. The aortic valve was significantly more frequently involved in 158 
enterococcal IE cases, while the tricuspid and pulmonary valve were more commonly 159 
affected in non-enterococcal IE. Around half of the cases in both groups had an unknown 160 
source of the infection. The median time elapsed between the appearance of symptoms and 161 
hospital admission was not different between the two groups. Genitourinary and 162 
gastrointestinal foci were significantly more common among enterococcal IE episodes; 163 
meanwhile, oral, vascular and cutaneous sources were significantly more frequent in the non-164 
enterococcal IE group. E. faecalis caused 90.7% of cases in the enterococcal IE group, being 165 
S. aureus, coagulase-negative staphylococci, and viridans group streptococci the more 166 
frequent causative agents in the non-enterococcal IE group. As for the proportion of cases 167 
from the global cohort, S. aureus represented 22.8%, coagulase-negative staphylococci 168 
17.4%, viridans group streptococci 16.1%, enterococci 13.5%, Bovis group streptococci 6.4% 169 
and other streptococci 5%. Enterococci accounted for 9.5% of cases in patients aged less than 170 
65 years and 16.4% among patients ≥65 years old (P<0.001). There were no cases of 171 
enterococcal IE caused by vancomycin-resistant enterococci. The site of acquisition did not 172 
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significantly differ between the two groups. Clinically, non-enterococcal IE presented with 173 
significantly higher rates of extensive CNS emboli, pulmonary emboli, and septic shock, as 174 
well as perivalvular abscesses, intracardiac fistula and pseudoaneurysm in the 175 
echocardiography, whereas enterococcal IE presented significantly higher rates of new onset 176 
heart failure and splenic abscesses. Enterococcal IE received a significantly longer median 177 
time of antibiotic therapy (42 vs. 36 days; P<0.001), being rates of cardiac surgery higher 178 
among non-enterococcal IE patients. Remarkably, 8 patients in the enterococcal IE group did 179 
not undergo cardiac surgery when indicated due to advanced liver disease, whereas this 180 
happened in 21 patients in the non-enterococcal group (1.5% vs. 0.6%; P=0.025, not shown).  181 
In-hospital and one-year mortality did not differ between both groups, yet relapses were 182 
significantly higher among patients with enterococcal IE.  183 
The characteristics and outcomes of enterococcal and non-enterococcal IE are compared in 184 
the Supplementary material among native valve IE cases (Supplementary Table 1), 185 
prosthetic valve IE cases (Supplementary Table 2) and patients undergoing cardiac surgery 186 
(Supplementary Table 3).  Notably, both in-hospital and one-year mortality were 187 
significantly higher among patients with non-enterococcal prosthetic valve IE, whereas 188 
relapses were significantly higher among patients with enterococcal prosthetic valve IE.  189 
A comparison of HCA vs. community-acquired enterococcal IE cases is shown in Table 2. 190 
Notably, HCA enterococcal cases more frequently involved prosthetic valves and had higher 191 
rates of chronic liver and renal disease, including dialysis, and transplantation, and 192 
immunosuppres therapy, whereas community-acquired enterococcal IE involved native 193 
valves significantly more frequently and presented higher rates of iv drug use and HIV 194 
infection. Outcomes did not significantly differ between the two groups.  195 
The characteristics and outcomes of enterococcal IE caused by E. faecalis are compared to 196 
those enterococcal IE cases caused by other species in Table 3. Of note, patients with E. 197 
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faecalis IE showed a trend to elder ages and presented significantly higher rates of chronic 198 
congestive heart failure, chronic dialysis, prosthetic valve IE, and paravalvular abscess. 199 
Patients with E. faecalis IE significantly received as initial antibiotic treatment double beta-200 
lactam combinations, whereas there were no differences between groups associated with 201 
beta-lactam plus aminoglycoside initial combinations. Non-E. faecalis IE was more 202 
frequently treated with other type of antibiotic treatment, being vancomycin combined with 203 
an aminoglycoside the third most common combination among E. faecalis IE patients. Ten 204 
(62.5%) of the 16 relapses occurring in patients with E. faecalis IE had received double beta-205 
lactam therapy, 5 (31.2%) received beta-lactam plus aminoglycosides and 1 (6.3%) 206 
vancomycin plus gentamicin. The two relapses occurring in non-E.faecalis IE patients had 207 
received other type of combinations. Outcomes did not significantly differ between the two 208 
groups.  209 
In the multivariate analysis, increasing age-adjusted Charlson score, paravalvular 210 
complications, new onset of heart failure, septic shock and logistic EuroSCORE were 211 
identified as risk factors for one-year mortality and prior episode of IE was protective. 212 
Persistent bacteremia was identified as a risk factor for relapse (Table 4). Curves for mortality 213 
and relapse over time are shown in the Central Illustration.   214 
 215 




Epidemiology and main clinical characteristics 218 
Ours is the largest national series of enterococcal IE described to date. In terms of 219 
epidemiological findings, this study confirms some of the common traits of the enterococcal 220 
IE profile described in studies conducted during the last fifteen years, but we also found some 221 
differences in this regard. Remarkably, as foreseen in the previous literature, median age, 222 
female sex, comorbidities, unknown source of infection and healthcare acquisition among 223 
enterococcal IE cases are on the rise. For example, Chirouze et al provided data on 500 cases 224 
of enterococcal IE from the International Collaboration on Endocarditis (ICE) collected from 225 
2000 to 2006 and compared them with 823 cases of IE caused by oral streptococci and 293 226 
cases of D group streptococcal IE [4]. North America was the region where more cases of 227 
enterococcal IE came from (50%), 90.6% of cases were caused by E. faecalis, median age 228 
was 65 years, 72.6% of cases occurred in men, 22.4% had diabetes, 8.4% were on chronic 229 
hemodialysis, 11.2% had cancer, 12.5% of cases had a prior episode of IE, 23.4% of cases 230 
overall were healthcare-associated and enterococcal IE involved prosthetic valves (in 29.1% 231 
of cases) significantly more frequently than streptococcal IE [4]. As in the case of another 232 
study from the ICE [23], we found that enterococcal IE is significantly more frequent among 233 
patients aged 65 years or more. By comparing to all other etiologies of IE, we have also 234 
identified that enterococcal IE is significantly less frequent among iv drug users, people 235 
living with HIV, patients with congenital heart disease, whereas it significantly more often 236 
the aortic valve and affected people with chronic diseases such as respiratory diseases, 237 
ischemic myocardiopathy, chronic heart failure, chronic renal disease or degenerative valve 238 
disease.  239 
From a clinical standpoint, the two major findings of our study are the high rate of prosthetic 240 
valve involvement and heart failure. In addition, we found that in spite of presenting very 241 
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similar profiles in all other aspects, E. faecalis produced significantly more prosthetic valve 242 
IE cases than other enterococcal species while the latter produced significantly more native 243 
valve IE, which has not been noted before.  244 
Complications and outcome 245 
Heart failure was a prognostic factor for mortality among patients with EE. However, when 246 
analyzing native and prosthetic valve IE separately, we did not find higher heart failure rates 247 
in prosthetic enterococcal IE. Heart failure as a common trait of enterococcal IE has 248 
previously been defined in some reports [24,25] but remarkably not in the Chirouze et al 249 
study [4]. In our cohort of enterococcal IE, we also find higher rates of moderate-severe 250 
aortic and mitral regurgitation than in other types of IE. We hypothesize this might be due to 251 
the higher frequency of heart abnormalities of elderly patients rather than to a special ability 252 
for valve tissue destruction inherent to enterococci, which is consistent with the lower rates of 253 
paravalvular complications we observed among patients with enterococcal IE and the fact 254 
than the median time elapsed from the onset of symptoms to admission was not different 255 
between enterococcal and non-enterococcal IE.  256 
Whereas we did not find significant differences in in-hospital and one-year mortality between 257 
enterococcal and non-enterococcal IE overall, both were significantly lower in enterococcal 258 
prosthetic valve IE than in non-enterococcal prosthetic valve IE in spite of the 259 
aforementioned lower rates of cardiac surgery. 260 
Although enterococcal IE classically presents with higher rates of relapse than other types of 261 
IE [8], the risk factors associated with this phenomenon have been scarcely investigated to 262 
date. Moreover, no other large study on enterococcal IE had previously confirmed a 263 
significantly higher rate, including the ICE study led by Chirouze, which did not provide data 264 
on relapses [4]. In our study, persistent bacteremia was found to be a risk factor for relapsing 265 
enterococcal IE. To the best of our knowledge, this is a novel finding. Persistent bacteremia 266 
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might be related to high initial bloodstream enterococcal inoculum, which may strongly 267 
depend on the source of the infection or the presence of intravascular devices, non-drained 268 
infectious foci and the type of initial antibiotic treatment, as well as to the characteristics of 269 
the bacterium. Persistent bacteremia, together with other recently identified potential risk 270 
factors for enterococcal IE relapses such as advanced liver disease [15] and genome 271 
modifications and phenotypic adaptation of changes of enterococcal strains [26] in E. faecalis 272 
IE, merit further investigation.  273 
Treatment features 274 
The length of antibiotic treatment was six weeks in median in both native and prosthetic 275 
valve enterococcal endocarditis. Among other determinants, this might reflect the high 276 
proportion of cases treated with double beta-lactam combination according to current 277 
guidelines [27,28], as well as the increasing complexity of enterococcal IE leading to six-278 
week courses also for ampicillin plus gentamicin provided the average complication rates that 279 
likely precludes the use of shorter courses. Furthermore, lesser patients with enterococcal IE 280 
had indication and did indeed undergo cardiac surgery, and again this general observation 281 
only kept true for patients with prosthetic valve IE (less than a third of whom were operated) 282 
and not for native valve IE. Almost two thirds among the latter had indication for cardiac 283 
surgery while it was barely 50% among patients with prosthetic valve IE. The leading 284 
indication for cardiac surgery among native valve enterococcal IE was congestive heart 285 
failure and valve regurgitation; both of them were significantly more common in native than 286 
in prosthetic enterococcal IE.  287 
Limitations 288 
This study is constrained by several limitations. Firstly, we could not assess the 289 
epidemiological evolution of enterococcal IE along the study period because the database was 290 
still being updated with case report forms from cases of 2015 and 2016 sent by participating 291 
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centers. Secondly, EE cases were compared to the rest of the GAMES cohort IE cases instead 292 
of being compared only to oral and D-group streptococcal IE. However, our findings strongly 293 
suggest that the profile of EE is no longer similar to that of to the classical community-294 
acquired streptococcal IE. Thirdly, due to a low proportion of cases including information of 295 
the antibiotic resistance profile of enterococci, we were not able to describe this aspect 296 
properly neither could we perform any analysis on the impact of high-level aminoglycoside 297 
resistance and vancomycin resistance on the prognosis of enterococcal IE. Fourthly, since 298 
most participating centers of the GAMES cohort are reference hospitals for cardiac surgery, 299 
the implications of a potential referral bias should be acknowledged. Fifth, the low number of 300 
non-E. faecalis enterococcal IE hampers the direct extrapolation of the results of the 301 
comparison between E. faecalis and non-E. faecalis IE. Finally, the long duration of the study 302 
period might represent a historical bias. 303 
Conclusions 304 
In conclusion, this study shows that enterococcal IE is an entity in constant evolution that 305 
constitutes the fourth common cause of IE in Spain. It affects mainly male and elderly 306 
patients with lots of comorbidities and prior episodes of IE; it is healthcare-associated in 307 
almost 50% of cases, involves prosthetic valves and entails heart failure and relapses more 308 
commonly than non-enterococcal IE. Although native enterococcal IE and non-enterococcal 309 
IE did not present significant differences on mortality rates, prosthetic valve enterococcal IE 310 
showed lower rates of in-hospital mortality and one-year mortality than non-enterococcal 311 
prosthetic IE. Relapses in enterococcal IE are associated to persistent bacteremia. Further 312 
studies investigating the relationship between relapses of enterococcal IE and potential 313 




Competency in Medical Knowledge 1: Enterococcal endocarditis is changing 316 
epidemiologically while becoming increasingly frequent worldwide.  317 
Competency in Medical Knowledge 2: Its clinical presentation is overall less severe than 318 
non-enterococcal endocarditis, yet it present higher rates of relapses and more frequently 319 
affects prosthetic valves.  320 
Competency in Medical Knowledge 3: The outcomes of Enterococcus faecalis endocarditis 321 
(almost 90% of enterococcal endocarditis cases) are not significantly different from those of 322 
non-E. faecalis enterococcal endocarditis.  323 
Competency in Patient Care: Enterococcal endocarditis should be suspected in elderly 324 
patients, especially in the healthcare setting. Follow-up after the initial admission is 325 
especially important due to an increased risk of relapses. 326 
Translational Outlook: Future research might encompass a multidimensional inquiry on the 327 
characteristics of the bacterium, the host and medical and surgical management underlying 328 
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Figure Legends 409 
Central Illustration.  410 
Mortality and relapses in enterococcal endocarditis vs. non-enterococcal endocarditis. 411 
(a) Kaplan-Meier curve for mortality at one year   412 
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Table 1.  Comparison of characteristics and outcome of enterococcal endocarditis and 436 
endocarditis caused by other microorganisms from the GAMES Cohort (2008-2016).  437 






Median age, years (IQR)  72 (64-78) 68 (55-77) <0.001 
Male sex (%)  357 (69.2%) 2206 (66.7%) 0.254 
Comorbidities     
Diabetes mellitus 168 (32.6%) 913 (27.6%) 0.025 
Chronic lung disease 139 (26.9%) 560 (16.9%) <0.001 
Ischemic cardiomyopathy 152 (29.5%) 841 (25.4%) 0.060 
Congestive heart failure 197 (38.2%) 1077 (32.6%) 0.014 
Moderate/severe liver disease 
   - Child Pugh score, mean (SD) 










Moderate/severe chronic renal failure 94 (18.2%) 489 (14.8%) 0.058 
Hemodialysis 24 (4.7%) 157 (4.7%) 0.924 
Neoplasm 94 (18.2%) 508 (15.4%) 0.114 
Transplantation 9 (1.7%) 64 (1.9%) 0.760 
Immunosuppressant therapy 38 (7.4%) 192 (5.8%) 0.201 
IV drug use 5 (1%) 78 (2.4%) 0.006 
HIV 4 (0.8%) 61 (1.8%) 0.018 
Previous IE 63 (12.2%) 215 (6.5%) <0.001 
Congenital cardiac abnormality 5 (1%) 218 (6.6%) <0.001 
20 
 
Non-congenital valve disease 252 (48.8%) 1431 (43.3%) 0.018 
Median age-adjusted Charlson score 
(IQR) 
5 (4-7) 4 (3-6) <0.001 
Type of endocarditis    
Native 324 (62.7%) 2007 (60.7%) 0.355 
Prosthetic* 185 (35.8%) 955 (28.9%) 0.002 
PCM/DF
+
 8 (1.5%) 346 (10.5%) <0.001 
Valve involvement
+
    
Aortic 332 (64.3%) 1545 (46.7%) <0.001 
Mitral 226 (43.8%) 1416 (42.8%) 0.672 
Tricuspid 15 (2.9%) 186 (5.6%) 0.001 
Pulmonary 0 51 (1.5%) <0.001 
Diagnosis of endocarditis according to 
modified Duke criteria 
  0.029 
Definite 431 (83.5%) 2626 (79.4%)  
Possible 85 (16.5%) 682 (20.6%)  
Median time of symptoms duration 
until admission in non-nosocomial 
cases, days (IQR) 
6.5 (1.3-22.8) 6.5 (2-18) 0.549 
Source     
Oral 8 (1.6%) 220 (6.7%) <0.001 
Respiratory 2 (0.4%) 40 (1.2%) 0.096 
Genitourinary 92 (17.8%) 106 (3.2%) <0.001 
Gastrointestinal 82 (15.9%) 172 (5.2%) <0.001 
Vascular 62 (12%) 637 (19.3%) <0.001 
Cutaneous 10 (1.9%) 260 (7.9%) <0.001 
21 
 
Other 19 (3.8%) 202 (6.3%) 0.031 
Unknown 262 (50.8%) 1708 (51.6%) 0.734 
Etiology   NA 
Enterococci 
- E. faecalis 
- E. faecium 




















Viridans group streptococci - 616 (18.6%)  
Coagulase-negative staphylococci - 664 (20.1%)  
Bovis group streptococci - 244 (7.4%)  
Other streptococci - 193 (5.8%)  
Other - 711 (21.5%)
×
  
Acquisition    
Community 282 (54.7%) 1953 (59%) 0.062 
Health-care associated 
- Nosocomial 










Unknown 15 (2.9%) 116 (3.5%) 0.486 
Clinical complications    
New onset or worsening heart failure 









- NYHA II 
- NYHA III 
- NYHA IV 
35 (15.1%) 
95 (40.9%) 







Persistent bacteremia 69 (13.4%) 378 (11.4%) 0.223 
CNS emboli 
- Hemorrhagic 
- Extensive (>2cm) 













Other major emboli 95 (18.4%) 687 (20.8%) 0.202 
Pulmonary emboli 6 (1.2%) 183 (5.5%) <0.001 
Vertebral osteomyelitis 18 (3.5%) 97 (2.9%) 0.479 
Non-vertebral osteomyelitis 6 (1.2%) 52 (1.6%) 0.536 
Renal abscess 14 (2.7%) 87 (2.6%) 0.914 
Splenic abscess 66 (12.8%) 310 (9.4%) 0.028 
Heart conduction abnormality 39 (7.6%) 297 (9%) 0.262 
Acute renal failure 191 (37%) 1177 (35.6%) 0.530 
Septic shock 37 (7.2%) 432 (13.1%) <0.001 
Echocardiographic findings    
TEE performed 391 (75.8%) 2583 (78.1%) 0.253 
Median ejection fraction (IQR) 60% (55-65) 60% (55-65) 0.536 
Median vegetation size in mm (IQR)  8 (3-14) 8 (3-14) 0.088 
Moderate-severe aortic regurgitation 193 (37.4%) 882 (26.7%) <0.001 
Moderate-severe mitral regurgitation 197 (38.2%) 1111 (33.6%) 0.048 
Perivalvular abscess 62 (12%) 514 (15.5%) 0.024 
23 
 
Intracardiac fistula 4 (0.8%) 86 (2.6%) <0.001 
Pseudoaneurysm 18 (3.5%) 183 (5.5%) 0.023 
Leaflet perforation/rupture 70 (13.6%) 436 (13.2%) 0.082 
Treatment characteristics    
Antibiotics properly indicated 493 (95.5%) 3168 (95.8%) 0.817 
Median length of antibiotic treatment, 
days (IQR) 
42 (30-46) 36 (24-44) <0.001 
Cardiac surgery 
- Indicated 
- Operated during admission 














Outcomes     
In-hospital mortality 123 (23.8%) 892 (27%) 0.123 
Mortality at 1-year 159 (30.8%) 1100 (33.3%) 0.266 
Relapses 18 (3.5%) 57 (1.7%) 0.035 
HIV: Human immunodeficiency syndrome; IQR: Interquartile range; MSSA: methicillin-438 
susceptible S. aureus; MRSA: methicillin-resistant S. aureus; NA: not analyzed; PCM/DF: 439 
pacemakers/defibrillators  440 
* 
There were 17 cases of endocarditis over TAVI, 3 of them occurring in the EE group and 14 441 
in the NEE group (0.5% vs. 0.4%, P=0.802). 442 
+
Only episodes in which only PCM/DF are affected are included in this group. Episodes have 443 
been classified as native or prosthetic valve where a concomitant valve involvement exists. 444 
The sum does not equal 100% because episodes with multivalve involvement are also 445 
counted.  446 
±
 In 9 cases there was not identification at the species level (Enterococcus spp.), whereas the 447 
3 remaining cases corresponded to one case of E. durans, E. avium and E. gallinarum each.  448 
×
Negative culture: 342 (48.1%); Gram negative bacilli: 163 (22.9%); Polymicrobial: 69 449 
(9.7%); Candida spp: 64 (9.0%); Anaerobic bacteria: 39 (5.5%); Other fungi: 11 (1.5%); 450 






Table 2. Comparison of Health-Care acquired vs. Community-acquired Enterococcal 453 
Endocarditis. 454 











Enterococcal species    0.342 
E. faecalis 256 (90.8%) 153 (91.1%) 47 (92.2%)  
E. faecium 17 (6%) 15 (8.9%) 4 (7.8%)  
Other 9 (3.2%)* 0 0  
Median age, years (IQR)  73 (64-80) 73 (64-78) 71 (62-79) 0.332 




Diabetes mellitus 97 (34.4%) 
46 (27.3%) 17 (33.3%) 
0.296 
Chronic lung disease 73 (25.9%) 
49 (29.1%) 
12 (23,5) 0.700 
Ischemic cardiomyopathy 78 (27.7%) 56 (33.3%) 12 (23.5%) 0.285 
Congestive heart failure 101 (35.8%) 74 (44%) 19 (37.2%) 0.221 
Moderate/severe liver disease 8 (2.8%) 7 (4.2%) 8 (15.7%) 0.022 
Moderate/severe chronic renal failure 43 (15.2%) 37 (22%) 12 (23.5%) 0.120 
Hemodialysis 4 (1.4%) 11 (6.5%) 8 (15.6%) <0.001 
Neoplasm 49 (17.4%) 28 (16.6%) 13 (25.4%) 0.329 
Transplantation 2 (0.7%) 6 (3.6%) 1 (2%) 0.806 
Immunosuppressant therapy 15 (5.3%) 18 (10.7%) 4 (7.8%) 0.105 
IV drug use 5 (1.8%) 0 0 0.024 
HIV 4 (1.4%) 0 0 0.045 
25 
 
Previous IE 28 (9.9%) 24 (14.2%) 10 (19.6%) 0.101 
Congenital cardiac abnormality 4 (1.4%) 2 (1.2%) 1 (2%) 0.918 
Non-congenital valve disease 134 (47.5%) 89 (52.9%) 23 (45%) 0.445 
Median age-adjusted Charlson score 
(IQR) 
5 (4-7) 
5 (4-7) 6 (4-8) 
0.425 
Type of endocarditis     
Native 192 (68.1%) 87 (51.7%) 37 (72.5%) <0.001 
Prosthetic 86 (30.5%) 79 (47%) 13 (25.4%) <0.001 






Aortic 179 (63.5%) 105 (62.5%) 37 (72.5%) 0.403 
Mitral 122 (43.3%) 75 (44.6%) 24 (47%) 0.868 
Tricuspid 10 (3.5%) 4 (2.4%) 1 (2%) 0.398 
Pulmonary 0 0 0 1.000 
Clinical complications  
 
  
New onset or worsening heart failure 126 (44.7%) 78 (46.7%) 23 (45.1%) 0.849 
Persistent bacteremia 36 (12.8%) 23 (13.7%) 8 (15.6%) 0.652 
CNS emboli 43 (15.2%) 30 (17.8%) 10 (19.6%) 0.372 
Other major emboli 57 (20.2%) 28 (16.7%) 6 (11.8%) 0.220 
Pulmonary emboli 2 (0.7%) 4 (2.3%) 0 0.280 
Vertebral osteomyelitis 9 (3.2%) 7 (4.1%) 2 (3.9%) 0.779 
Non-vertebral osteomyelitis 5 (1.8%) 0 1 (1.9%) 0.152 
Renal abscess 8 (2.8%) 0 0 0.695 
Splenic abscess 40 (14.2%) 6 (3.5%) 3 (5.8%) <0.001 
Heart conduction abnormality 22 (7.8%) 12 (7.1%) 3 (5.8%) 0.880 
26 
 
Acute renal failure 112 (39.7%) 51 (30.3%) 19 (37.2%) 0.134 
Septic shock 19 (6.7%) 14 (8.3%) 3 (5.8%) 0.761 
Echocardiographic findings   
 
  
TEE performed 206 (73%) 134 (79.8%) 40 (78.4%) 0.093 
Median ejection fraction (%, IQR) 60 (55-65) 60 (50-65) 60 (50-68) 0.465 
Median vegetation size (mm, IQR) 8 (3-15) 10 (7-19) 10.5 (8-13) 0.729 
Moderate-severe aortic regurgitation 107 (37.9%) 54 (32.1%) 24 (47%) 0.133 
Moderate-severe mitral regurgitation 119 (42.2%) 49 (29.1%) 25 (49%) 0.006 
Perivalvular abscess 23 (8.2%) 28 (16.6%) 9 (17.6%) 0.011 
Intracardiac fistula 2 (0.7%) 2 (1.2%) 0 0.235 
Pseudoaneurysm 5 (1.8%) 6 (3.6%) 5 (9.8%) 0.010 
Leaflet perforation/rupture 44 (15.6%) 19 (11.3%) 6 (11.7%) 0.163 
Treatment characteristics     
Median length of antibiotic treatment, 
days (IQR) 
42 (29-46) 
42 (33-47) 42 (28-46) 
0.317 
Cardiac surgery 121 (42.9%) 57 (33.9%) 23 (45.1%) 0.127 
Outcomes     
In-hospital mortality 60 (21.3%) 45 (25.5%) 16 (31.3%) 0.186 
One-year mortality 79 (28%) 53 (31.5%) 22 (43.1%) 0.094 
Relapses
±
 10 (3.5%) 3 (1.7%) 4 (7.8%) 0.109 
*
 8 cases due to Enterococcus spp. and 1 case of E. durans IE 455 
± 
One case of relapse among EE was not included because it had an unknown source of 456 




Table 3. Comparison of E. faecalis vs. non-E. faecalis Enterococcal Endocarditis 459 
   E. faecalis IE 
(N=468) 
Non-E. faecalis IE 
(N=48) 
P 
Median age, years (IQR)  73 (64.5-79) 68.5 (59.5-76) 0.080 
Male sex (%)  325 (69.4%) 32 (66.7%) 0.697 
Comorbidities    
Diabetes mellitus 151 (32.3%) 17 (35.4%) 0.663 
Chronic lung disease 130 (27.8%) 9 (18.8%) 0.133 
Ischemic cardiomyopathy 140 (29.9%) 12 (25%) 0.457 
Congestive heart failure 187 (40%) 10 (20.8%) 0.002 
Moderate/severe liver disease 20 (4.3%) 4 (8.3%) 0.322 
Moderate/severe chronic renal failure 88 (18.8%) 6 (12.5%) 0.217 
Hemodialysis 24 (5.1%) 0 <0.001 
Neoplasm 81 (17.3%) 13 (27.1%) 0.142 
Transplantation 8 (1.7%) 1 (2.1%) 0.862 
Immunosuppressant therapy 33 (7.1%) 5 (10.4%) 0.461 
IV drug use 4 (0.9%) 1 (2.1%) 0.560 
HIV 3 (0.6%) 1 (2.1%) 0.491 
Previous IE 57 (12.2%) 6 (12.5%) 0.949 
Congenital cardiac abnormality 6 (1.3%) 1 (2.1%) 0.706 
Non-congenital valve disease 229 (48.9%) 23 (47.9%) 0.893 
Median age-adjusted Charlson score (IQR) 5 (4-7) 5 (3-7) 0.227 
Type of endocarditis    
Native 287 (61.3%) 37 (77.1%) 0.015 
Prosthetic 174 (37.2%) 11 (22.9%) 0.028 





    
Aortic 302 (64.5%) 30 (62.5%) 0.782 
Mitral 203 (43.4%) 23 (47.9%) 0.549 
Tricuspid 14 (3%) 1 (2.1%) 0.681 
Pulmonary 0 0 1.000 
Acquisition    
Community 256 (54.7%) 26 (54.2%) 0.944 
Health-care associated 
- Nosocomial 










Unknown 15 (3.2%) 0 0.124 
Clinical complications     
New onset or worsening heart failure 214 (45.7%) 18 (37.5%) 0.264 
Persistent bacteremia 61 (13%) 8 (16.7) 0.517 
CNS emboli 75 (16%) 11 (22.9%) 0.274 
Other major emboli 85 (18.2%) 10 (20.8%) 0.663 
Pulmonary emboli 4 (0.9%) 2 (4.2%) 0.256 
Vertebral osteomyelitis  17 (3.6%) 1 (2.1%) 0.577 
Non-vertebral osteomyelitis  6 (1.3%) 0 0.358 
Renal abscess 12 (2.6%) 2 (4.2%) 0.590 
Splenic abscess 60 (12.8%) 6 (12.5%) 0.949 
Heart conduction abnormality 36 (7.7%) 3 (6.3%) 0.697 
Acute renal failure 172 (36.8%) 19 (39.6%) 0.702 
Septic shock 31 (6.6%) 6 (12.5%) 0.232 
Echocardiographic findings    
TEE performed 358 (76.5%) 33 (68.8%) 0.267 
Median ejection fraction (IQR) 60 (55-66) 60 (55-65) 0.805 
29 
 
Median vegetation size, mm (IQR) 8 (3-14) 6 (3-8) 0.110 
Moderate-severe aortic regurgitation 179 (38.2%) 14 (29.2%) 0.191 
Moderate-severe mitral regurgitation 183 (39.1%) 14 (209.2%) 0.153 
Paravalvular abscess 60 (12.8%) 2 (4.2%) 0.008 
Intracardiac fistula 3 (0.6%) 1 (2.1%) 0.491 
Pseudoaneurysm 16 (3.4%) 2 (4.2%) 0.803 
Leaflet perforation/rupture 63 (13.5%) 7 (14.6%) 0.585 
Treatment characteristics    
Median length of antibiotic treatment, 
days (IQR)  
42 (30-46) 42 (28-44) 0.389 
Cardiac surgery 192 (41%) 18 (37.5%) 0.632 
Initial antibiotic treatment 
- Double beta-lactam combination 
















Outcomes    
In-hospital mortality 109 (23.3%) 14 (29.2%) 0.391 
Mortality at 1-year 144 (30.8%) 15 (31.3%) 0.945 
Relapses 16 (3.4%) 2 (4.2%) 0.803 
± Vancomycin plus aminoglycoside: 11 (20.4%); Vancomycin plus other: 8 (14.8%); 460 
Daptomycin: 7 (13%); Daptomycin plus beta-lactam: 5 (9.3%); Daptomycin plus fosfomycin: 461 
1 (1.8%); Beta-lactam alone: 7 (13%); Beta-lactam plus quinolone: 4 (7.4%); Linezolid: 2 462 




Table 4. Analysis of Risk Factors for In-Hospital Mortality, One-year Mortality and Relapses for 516 cases of Enterococcal 465 
Endocarditis. 466 
   One-Year Mortality Relapses 
   Univariate Multivariate Univariate Multivariate 
   HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI) P 
E. faecalis 0.99 (0.58, 1.68) 0.970   






N.A.    
Male sex  0.94 (0.67, 1.31) 0.722 
  
0.44 (0.16, 1.17) 0.103 0.50 (0.19, 1.36) 0.174 
Age (years)  1.00 (0.99, 1.01) 0.534 
  
1.02 (0.98, 1.07) 0.322   
Diabetes mellitus 1.56 (1.14, 2.14) 0.006 1.00 (0.63, 1.62) 0.972 
0.69 (0.22, 2.14) 0.524   
Congestive heart 
failure 
1.10 (0.80, 1.51) 0.561 
  
0.98 (0.36, 2.70) 0.976   
Moderate-severe 
chronic renal failure 
1.97 (1.40, 2.79) <0.001 
  
1.05 (0.30, 3.67) 0.943   
Moderate-severe liver 
disease  
2.58 (2.52, 4.40) <0.001 2.62 (1.31, 5.24) 0.007 
2.95 (0.67, 12.96) 0.152 2.03 (0.45, 9.16) 0.351 
31 
 
Previous IE 0.53 (0.30, 0.96) 0.041 0.42 (0.21, 0.84) 0.012 2.45 (0.79, 7.59) 0.124   
Age-adjusted 
Charlson score  
1.16 (1.10, 1.23) <0.001 
1.12 (1.01, 1.24) 0.010 
0.93 (0.76, 1.14) 0.497   
Community 
acquisition  
0.79 (0.58, 1.08) 0.154 
  
1.17 (0.42, 3.29) 0.765   
Prosthetic IE 0.78 (0.56, 1.09) 0.158 
  
1.82 (0.68, 4.85) 0.232   
Urinary source 1.31 (0.89, 1.91) 0.172   
0.65 (0.15, 2.85) 0.576   
Aortic valve IE  1.08 (0.78, 1.50) 0.623 
  
0.42 (0.16, 1.14) 0.094 0.42 (0.16, 1.15) 0.095 
Mitral valve IE 1.07 (0.79, 1.48) 0.602   
2.15 (0.78, 5.92) 0.133 1.67 (0.49, 5.78) 0.412 
Paravalvular 
complications*  
1.52 (1.09, 2.12) 0.014 
1.87 (1.22, 2.87) 0.040 
0.19 (0.03, 1.43) 0.115 0.22 (0.03, 1.73) 0.153 
Vegetation size ≥ 
10mm 
0.79 (0.46, 1.37) 0.414 
  
0.96 (0.16, 5.72) 0.961   
New onset heart 
failure  
2.37 (1.72, 3.27) <0.001 
2.42 (1.53, 3.83) <0.001 
0.94 (0.35, 2.52) 0.904   
32 
 
Persistent bacteremia  1.37 (0.90, 2.07) 0.143 
  
3.99 (1.45, 10.98) 0.007 4.03 (1.43, 11.33) 0.008 
CNS emboli  1.23 (0.83, 1.83) 0.313 
  
1.12 (0.32, 3.94) 0.852   
Other emboli  1.05 (0.71, 1.57) 0.787 
  
0.99 (0.28, 3.48) 0.993   
New heart conduction 
abnormality  
1.58 (0.94, 2.66) 0.082 
  
N.A.    
Acute renal failure  1.86 (1.36, 2.54) <0.001 
1.30 (0.84, 2.00) 0.241 
1.31 (0.49, 3.52) 0.589   
Septic shock  3.09 (1.99, 4.77 <0.001 1.76 (1.04, 2.99) 0.033 
N.A.    
Inappropriate initial 
antibiotics  
1.71 (0.90, 3.25) 0.102 
  
N.A.    
Cardiac surgery  0.62 (0.45, 0.87) 0.006 0.88 (0.54, 1.43) 0.613 
0.33 (0.09, 1.15) 0.083 0.48 (0.13, 1.71) 0.253 
Logistic EuroSCORE  1.02 (1.01, 1.03 <0.001 
1.02 (1.01, 1.03) 0.002 
1.00 (0.98, 1.03) 0.923   
* Paravalvular complications include at least one of the following: periannular abscess, pseudoaneurysm, fistula, or leaflet perforation/rupture. 467 
N.A.= Non-assessed due to low number of events468 
33 
 
Central Illustration. Mortality and relapses in enterococcal endocarditis vs. non-469 
enterococcal endocarditis. (a) Kaplan-Meier curve for mortality at one year; (b) Kaplan-Meier 470 
curve for relapses over time. 471 













 * Shown in other large series 483 
 484 
Clinical areas and patient features in which enterococcal endocarditis is of 
special relevance:  
- Elderly patients 
- TAVI* 
- Prosthetic valve endocarditis 
- Degenerative left-sided valve disease 
- Aortic involvement 
- Chronic lung disease 
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Abstract  51 
 52 
Background: Enterococcal endocarditis (EE) is a growing entity in Western countries. 53 
However, quality data from large studies is lacking.  54 
Objectives: To describe the characteristics and analyze the prognostic factors of EE in the 55 
GAMES cohort. 56 
Methods: Post-hoc analysis of a prospectively collected cohort of patients from 35 Spanish 57 
centers from 2008 to 2016. Characteristics and outcomes of 516 cases of EE were compared 58 
to those of 3,308 cases of non-enterococcal endocarditis (NEE). Logistic regression and Cox 59 
proportional hazards regression analysis were performed to investigate risk factors for in-hospital and 60 
one-year mortality, and relapses.  61 
Results: Patients with EE were significantly older, presented more frequently chronic lung 62 
disease, chronic heart failure, prior endocarditis, degenerative valve disease and had higher 63 
median age-adjusted Charlson score. EE more frequently involved the aortic valve and 64 
prosthesis (64.3% vs. 46.7%; P<0.001; and 35.9% vs. 28.9%; P=0.002, respectively) but less 65 
frequently pacemakers/defibrillators (1.5% vs. 10.5%; P<0.001), and showed higher rates of 66 
acute heart failure (45% vs. 38.3%;P=0.005). Cardiac surgery was less frequently performed 67 
in EE (40.7% vs.45.9%;P=0.024). No differences in in-hospital mortality and one-year 68 
mortality were found, whereas relapses were significantly higher in EE (3.5% vs. 1.7%; 69 
P=0.035). Increasing Charlson score, LogEuroSCORE, acute heart failure, septic shock and 70 
paravalvular complications were risk factors for mortality, whereas prior endocarditis was 71 
protective and persistent bacteremia constituted the sole risk factor for relapse. 72 
Conclusions: Besides other baseline and clinical differences, EE more frequently affects 73 
prosthetic valves and less frequently pacemakers/defibrillators. EE presents higher rates of 74 
relapse than NEE.  75 
 76 
Condensed abstract: Enterococcal endocarditis (EE) is a growing issue in Western 77 
countries. By comparing 516 cases of EE with 3,308 cases of NEE, we found older median 78 
age and higher comorbidity rates among EE than in NEE, as well as higher rates of aortic 79 
valve and prosthetic valve involvement, and heart failure. Mortality did not significantly 80 
differ between EE and NEE, whereas relapses were higher in EE. Risk factors for mortality in 81 
EE were Charlson score, LogEuroSCORE, acute heart failure, septic shock and paravalvular 82 
complications, whereas persistent bacteremia was associated with a higher likelihood of 83 
relapses.  84 
 85 
Keywords: Infective endocarditis, enterococci, heart failure, relapses, prosthetic valves, 86 
epidemiology.  87 
 88 
Abbreviations: CNS, central nervous system; EE, enterococcal endocarditis; HCA, 89 
healthcare-associated; IE, infective endocarditis; MRSA, methicillin-resistant S. aureus; 90 
NEE, non-enterococcal endocarditis; PCM/DF, pacemakers/defibrillators; TAVI, transaortic 91 




Enterococci have been identified as a growing pathogen, primarily in health-care associated 94 
infections in the U.S., where vancomycin-resistant strains pose a serious challenge to the 95 
health system [1]. However, enterococci are also playing an increasingly important role in 96 
infective endocarditis (IE) [2], with most recent series placing it as the third leading causative 97 
agent in high-income countries, reaching up to 15-20% of total cases [3-6]. Moreover, 98 
enterococci are the leading causative agent of transaortic valve implants (TAVI)-associated 99 
IE [7]. 100 
Most cases (around 90%) of enterococcal IE are caused by E. faecalis [8]. Since the turn of 101 
the 21
st
 century, the classically described clinical presentation of enterococcal IE as a 102 
community-acquired, subacute pauci-symptomatic disease of genitourinary source [10] is 103 
progressively turning in a more aggressive, acute, more frequently healthcare-associated 104 
(HCA) disease of occurring predominantly amongst elderly patients with a large burden of 105 
comorbidities and seldom a clear identifiable source. [9,10].  106 
The focus of recent relevant studies addressing enterococcal IE is largely placed on the 107 
genetic and molecular aspects [11,12], impact of antimicrobial resistance (e.g. vancomycin, 108 
high-level aminoglycoside resistance and daptomycin resistance) [1,8,11,12], therapeutic 109 
options [13-15] or the use of TEE to detect IE [16-18], whereas there is a relative paucity of 110 
studies explaining the main clinical and epidemiological changes of enterococcal IE in the 111 
last two decades and their underlying mechanisms, such as its potential association with 112 
colorectal neoplasms [19,20].  113 
We aimed to investigate the main characteristics of enterococcal IE in a cohort of 516 114 
patients prospectively collected from 2008 to 2016 and to compare them with those of non-115 




Design: multicenter prospective observational study including 35 Spanish centers between 118 
2008 and 2016. The characteristics of the GAMES cohort, collection of data variables 119 
through a specific central registration depository, and definitions are described elsewhere [5]. 120 
The work-up for searching potential sources of the infection, including gastrointestinal tract 121 
screening, was not systematic but was decided by the treating physician. Persistent 122 
bacteremia was defined as positive blood cultures beyond seven days of effective antibiotic 123 
therapy; relapse refers to a new episode of IE due to the same microorganism within the next 124 
6 months after the initial episode; acute renal failure was defined in the data collection sheet 125 
as a worsening equal or higher than 25% of serum creatinine or glomerular clearance 126 
occurring within a lapse of 72h; community-acquired IE was defined as IE diagnosed within 127 
the first 48 hours of admission in a patient who did not fulfill the criteria for HCA infection. 128 
HCA infection encompasses nosocomial and non-nosocomial HCA IE [21]. Nosocomial IE 129 
was defined as IE in a patient who had been hospitalized for >48 hours before the onset of 130 
signs or symptoms consistent with IE. Non-nosocomial HCA IE was an IE diagnosed within 131 
48 hours of admission of an outpatient. 132 
Patients: adult individuals with definite or possible IE diagnosed according to the modified 133 
Duke criteria [22].  134 
Outcomes: in-hospital and one-year mortality (death due to any causes within 30 days and 135 
365 days from the admission, respectively), and relapses.  136 
Statistical analysis: Categorical variables were summarized as percentages and continuous 137 
variables as means and standard deviations. Categorical variables were compared using the 138 
chi-square test (or Fisher’s exact test where necessary). Continuous variables were compared 139 
using the Kruskal-Wallis test. Cox proportional hazards regression analysis was utilized to 140 
investigate risk factors for one-year mortality and relapses. Variables with P<0.20 in the 141 
5 
 
univariate analysis were included in the models. Kaplan-Meier survival curves free of 142 
mortality at one year and relapses were generated with log-rank test analysis and considering 143 
censored episodes according to the time measured for each endpoint. A two-sided P<0.05 144 
was considered to be statistically significant. Statistical analyses were performed using SPSS 145 
for Windows, Version 16.0 (SPSS Inc, Chicago, Illinois, USA). 146 




Patients with enterococcal IE were significantly older and had higher rates of comorbidities, 149 
leading to a significantly higher median age-adjusted Charlson score (Table 1). Diabetes 150 
mellitus, chronic lung disease, congestive heart failure, previous IE, and non-congenital valve 151 
disease were all significantly more frequent among enterococcal IE, whereas ischemic 152 
cardiomyopathy and chronic renal failure, although more frequent too among enterococcal 153 
IE, did not reach statistical significance. On the other hand, iv drug use, HIV infection and 154 
congenital heart abnormalities were significantly more common among patients with non-155 
enterococcal IE. The proportion of prosthetic valve IE was significantly higher in the 156 
enterococcal IE group, whereas PCM/DF-associated IE was significantly more frequent in the 157 
non-enterococcal IE group. The aortic valve was significantly more frequently involved in 158 
enterococcal IE cases, while the tricuspid and pulmonary valve were more commonly 159 
affected in non-enterococcal IE. Around half of the cases in both groups had an unknown 160 
source of the infection. The median time elapsed between the appearance of symptoms and 161 
hospital admission was not different between the two groups. Genitourinary and 162 
gastrointestinal foci were significantly more common among enterococcal IE episodes; 163 
meanwhile, oral, vascular and cutaneous sources were significantly more frequent in the non-164 
enterococcal IE group. E. faecalis caused 90.7% of cases in the enterococcal IE group, being 165 
S. aureus, coagulase-negative staphylococci, and viridans group streptococci the more 166 
frequent causative agents in the non-enterococcal IE group. As for the proportion of cases 167 
from the global cohort, S. aureus represented 22.8%, coagulase-negative staphylococci 168 
17.4%, viridans group streptococci 16.1%, enterococci 13.5%, Bovis group streptococci 6.4% 169 
and other streptococci 5%. Enterococci accounted for 9.5% of cases in patients aged less than 170 
65 years and 16.4% among patients ≥65 years old (P<0.001). There were no cases of 171 
enterococcal IE caused by vancomycin-resistant enterococci. The site of acquisition did not 172 
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significantly differ between the two groups. Clinically, non-enterococcal IE presented with 173 
significantly higher rates of extensive CNS emboli, pulmonary emboli, and septic shock, as 174 
well as perivalvular abscesses, intracardiac fistula and pseudoaneurysm in the 175 
echocardiography, whereas enterococcal IE presented significantly higher rates of new onset 176 
heart failure and splenic abscesses. Enterococcal IE received a significantly longer median 177 
time of antibiotic therapy (42 vs. 36 days; P<0.001), being rates of cardiac surgery higher 178 
among non-enterococcal IE patients. Remarkably, 8 patients in the enterococcal IE group did 179 
not undergo cardiac surgery when indicated due to advanced liver disease, whereas this 180 
happened in 21 patients in the non-enterococcal group (1.5% vs. 0.6%; P=0.025, not shown).  181 
In-hospital and one-year mortality did not differ between both groups, yet relapses were 182 
significantly higher among patients with enterococcal IE.  183 
The characteristics and outcomes of enterococcal and non-enterococcal IE are compared in 184 
the Supplementary material among native valve IE cases (Supplementary Table 1), 185 
prosthetic valve IE cases (Supplementary Table 2) and patients undergoing cardiac surgery 186 
(Supplementary Table 3).  Notably, both in-hospital and one-year mortality were 187 
significantly higher among patients with non-enterococcal prosthetic valve IE, whereas 188 
relapses were significantly higher among patients with enterococcal prosthetic valve IE.  189 
A comparison of HCA vs. community-acquired enterococcal IE cases is shown in Table 2. 190 
Notably, HCA enterococcal cases more frequently involved prosthetic valves and had higher 191 
rates of chronic liver and renal disease, including dialysis, and transplantation, and 192 
immunosuppres therapy, whereas community-acquired enterococcal IE involved native 193 
valves significantly more frequently and presented higher rates of iv drug use and HIV 194 
infection. Outcomes did not significantly differ between the two groups.  195 
The characteristics and outcomes of enterococcal IE caused by E. faecalis are compared to 196 
those enterococcal IE cases caused by other species in Table 3. Of note, patients with E. 197 
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faecalis IE showed a trend to elder ages and presented significantly higher rates of chronic 198 
congestive heart failure, chronic dialysis, prosthetic valve IE, and paravalvular abscess. 199 
Patients with E. faecalis IE significantly received as initial antibiotic treatment double beta-200 
lactam combinations, whereas there were no differences between groups associated with 201 
beta-lactam plus aminoglycoside initial combinations. Non-E. faecalis IE was more 202 
frequently treated with other type of antibiotic treatment, being vancomycin combined with 203 
an aminoglycoside the third most common combination among E. faecalis IE patients. Ten 204 
(62.5%) of the 16 relapses occurring in patients with E. faecalis IE had received double beta-205 
lactam therapy, 5 (31.2%) received beta-lactam plus aminoglycosides and 1 (6.3%) 206 
vancomycin plus gentamicin. The two relapses occurring in non-E.faecalis IE patients had 207 
received other type of combinations. Outcomes did not significantly differ between the two 208 
groups.  209 
In the multivariate analysis, increasing age-adjusted Charlson score, paravalvular 210 
complications, new onset of heart failure, septic shock and logistic EuroSCORE were 211 
identified as risk factors for one-year mortality and prior episode of IE was protective. 212 
Persistent bacteremia was identified as a risk factor for relapse (Table 4). Curves for mortality 213 
and relapse over time are shown in the Central Illustration.   214 
 215 




Epidemiology and main clinical characteristics 218 
Ours is the largest national series of enterococcal IE described to date. In terms of 219 
epidemiological findings, this study confirms some of the common traits of the enterococcal 220 
IE profile described in studies conducted during the last fifteen years, but we also found some 221 
differences in this regard. Remarkably, as foreseen in the previous literature, median age, 222 
female sex, comorbidities, unknown source of infection and healthcare acquisition among 223 
enterococcal IE cases are on the rise. For example, Chirouze et al provided data on 500 cases 224 
of enterococcal IE from the International Collaboration on Endocarditis (ICE) collected from 225 
2000 to 2006 and compared them with 823 cases of IE caused by oral streptococci and 293 226 
cases of D group streptococcal IE [4]. North America was the region where more cases of 227 
enterococcal IE came from (50%), 90.6% of cases were caused by E. faecalis, median age 228 
was 65 years, 72.6% of cases occurred in men, 22.4% had diabetes, 8.4% were on chronic 229 
hemodialysis, 11.2% had cancer, 12.5% of cases had a prior episode of IE, 23.4% of cases 230 
overall were healthcare-associated and enterococcal IE involved prosthetic valves (in 29.1% 231 
of cases) significantly more frequently than streptococcal IE [4]. As in the case of another 232 
study from the ICE [23], we found that enterococcal IE is significantly more frequent among 233 
patients aged 65 years or more. By comparing to all other etiologies of IE, we have also 234 
identified that enterococcal IE is significantly less frequent among iv drug users, people 235 
living with HIV, patients with congenital heart disease, whereas it significantly more often 236 
the aortic valve and affected people with chronic diseases such as respiratory diseases, 237 
ischemic myocardiopathy, chronic heart failure, chronic renal disease or degenerative valve 238 
disease.  239 
From a clinical standpoint, the two major findings of our study are the high rate of prosthetic 240 
valve involvement and heart failure. In addition, we found that in spite of presenting very 241 
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similar profiles in all other aspects, E. faecalis produced significantly more prosthetic valve 242 
IE cases than other enterococcal species while the latter produced significantly more native 243 
valve IE, which has not been noted before.  244 
Complications and outcome 245 
Heart failure was a prognostic factor for mortality among patients with EE. However, when 246 
analyzing native and prosthetic valve IE separately, we did not find higher heart failure rates 247 
in prosthetic enterococcal IE. Heart failure as a common trait of enterococcal IE has 248 
previously been defined in some reports [24,25] but remarkably not in the Chirouze et al 249 
study [4]. In our cohort of enterococcal IE, we also find higher rates of moderate-severe 250 
aortic and mitral regurgitation than in other types of IE. We hypothesize this might be due to 251 
the higher frequency of heart abnormalities of elderly patients rather than to a special ability 252 
for valve tissue destruction inherent to enterococci, which is consistent with the lower rates of 253 
paravalvular complications we observed among patients with enterococcal IE and the fact 254 
than the median time elapsed from the onset of symptoms to admission was not different 255 
between enterococcal and non-enterococcal IE.  256 
Whereas we did not find significant differences in in-hospital and one-year mortality between 257 
enterococcal and non-enterococcal IE overall, both were significantly lower in enterococcal 258 
prosthetic valve IE than in non-enterococcal prosthetic valve IE in spite of the 259 
aforementioned lower rates of cardiac surgery. 260 
Although enterococcal IE classically presents with higher rates of relapse than other types of 261 
IE [8], the risk factors associated with this phenomenon have been scarcely investigated to 262 
date. Moreover, no other large study on enterococcal IE had previously confirmed a 263 
significantly higher rate, including the ICE study led by Chirouze, which did not provide data 264 
on relapses [4]. In our study, persistent bacteremia was found to be a risk factor for relapsing 265 
enterococcal IE. To the best of our knowledge, this is a novel finding. Persistent bacteremia 266 
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might be related to high initial bloodstream enterococcal inoculum, which may strongly 267 
depend on the source of the infection or the presence of intravascular devices, non-drained 268 
infectious foci and the type of initial antibiotic treatment, as well as to the characteristics of 269 
the bacterium. Persistent bacteremia, together with other recently identified potential risk 270 
factors for enterococcal IE relapses such as advanced liver disease [15] and genome 271 
modifications and phenotypic adaptation of changes of enterococcal strains [26] in E. faecalis 272 
IE, merit further investigation.  273 
Treatment features 274 
The length of antibiotic treatment was six weeks in median in both native and prosthetic 275 
valve enterococcal endocarditis. Among other determinants, this might reflect the high 276 
proportion of cases treated with double beta-lactam combination according to current 277 
guidelines [27,28], as well as the increasing complexity of enterococcal IE leading to six-278 
week courses also for ampicillin plus gentamicin provided the average complication rates that 279 
likely precludes the use of shorter courses. Furthermore, lesser patients with enterococcal IE 280 
had indication and did indeed undergo cardiac surgery, and again this general observation 281 
only kept true for patients with prosthetic valve IE (less than a third of whom were operated) 282 
and not for native valve IE. Almost two thirds among the latter had indication for cardiac 283 
surgery while it was barely 50% among patients with prosthetic valve IE. The leading 284 
indication for cardiac surgery among native valve enterococcal IE was congestive heart 285 
failure and valve regurgitation; both of them were significantly more common in native than 286 
in prosthetic enterococcal IE.  287 
Limitations 288 
This study is constrained by several limitations. Firstly, we could not assess the 289 
epidemiological evolution of enterococcal IE along the study period because the database was 290 
still being updated with case report forms from cases of 2015 and 2016 sent by participating 291 
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centers. Secondly, EE cases were compared to the rest of the GAMES cohort IE cases instead 292 
of being compared only to oral and D-group streptococcal IE. However, our findings strongly 293 
suggest that the profile of EE is no longer similar to that of to the classical community-294 
acquired streptococcal IE. Thirdly, due to a low proportion of cases including information of 295 
the antibiotic resistance profile of enterococci, we were not able to describe this aspect 296 
properly neither could we perform any analysis on the impact of high-level aminoglycoside 297 
resistance and vancomycin resistance on the prognosis of enterococcal IE. Fourthly, since 298 
most participating centers of the GAMES cohort are reference hospitals for cardiac surgery, 299 
the implications of a potential referral bias should be acknowledged. Fifth, the low number of 300 
non-E. faecalis enterococcal IE hampers the direct extrapolation of the results of the 301 
comparison between E. faecalis and non-E. faecalis IE. Finally, the long duration of the study 302 
period might represent a historical bias. 303 
Conclusions 304 
In conclusion, this study shows that enterococcal IE is an entity in constant evolution that 305 
constitutes the fourth common cause of IE in Spain. It affects mainly male and elderly 306 
patients with lots of comorbidities and prior episodes of IE; it is healthcare-associated in 307 
almost 50% of cases, involves prosthetic valves and entails heart failure and relapses more 308 
commonly than non-enterococcal IE. Although native enterococcal IE and non-enterococcal 309 
IE did not present significant differences on mortality rates, prosthetic valve enterococcal IE 310 
showed lower rates of in-hospital mortality and one-year mortality than non-enterococcal 311 
prosthetic IE. Relapses in enterococcal IE are associated to persistent bacteremia. Further 312 
studies investigating the relationship between relapses of enterococcal IE and potential 313 




Competency in Medical Knowledge 1: Enterococcal endocarditis is changing 316 
epidemiologically while becoming increasingly frequent worldwide.  317 
Competency in Medical Knowledge 2: Its clinical presentation is overall less severe than 318 
non-enterococcal endocarditis, yet it present higher rates of relapses and more frequently 319 
affects prosthetic valves.  320 
Competency in Medical Knowledge 3: The outcomes of Enterococcus faecalis endocarditis 321 
(almost 90% of enterococcal endocarditis cases) are not significantly different from those of 322 
non-E. faecalis enterococcal endocarditis.  323 
Competency in Patient Care: Enterococcal endocarditis should be suspected in elderly 324 
patients, especially in the healthcare setting. Follow-up after the initial admission is 325 
especially important due to an increased risk of relapses. 326 
Translational Outlook: Future research might encompass a multidimensional inquiry on the 327 
characteristics of the bacterium, the host and medical and surgical management underlying 328 
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Figure Legends 409 
Central Illustration.  410 
Mortality and relapses in enterococcal endocarditis vs. non-enterococcal endocarditis. 411 
(a) Kaplan-Meier curve for mortality at one year   412 
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Table 1.  Comparison of characteristics and outcome of enterococcal endocarditis and 436 
endocarditis caused by other microorganisms from the GAMES Cohort (2008-2016).  437 






Median age, years (IQR)  72 (64-78) 68 (55-77) <0.001 
Male sex (%)  357 (69.2%) 2206 (66.7%) 0.254 
Comorbidities     
Diabetes mellitus 168 (32.6%) 913 (27.6%) 0.025 
Chronic lung disease 139 (26.9%) 560 (16.9%) <0.001 
Ischemic cardiomyopathy 152 (29.5%) 841 (25.4%) 0.060 
Congestive heart failure 197 (38.2%) 1077 (32.6%) 0.014 
Moderate/severe liver disease 
   - Child Pugh score, mean (SD) 










Moderate/severe chronic renal failure 94 (18.2%) 489 (14.8%) 0.058 
Hemodialysis 24 (4.7%) 157 (4.7%) 0.924 
Neoplasm 94 (18.2%) 508 (15.4%) 0.114 
Transplantation 9 (1.7%) 64 (1.9%) 0.760 
Immunosuppressant therapy 38 (7.4%) 192 (5.8%) 0.201 
IV drug use 5 (1%) 78 (2.4%) 0.006 
HIV 4 (0.8%) 61 (1.8%) 0.018 
Previous IE 63 (12.2%) 215 (6.5%) <0.001 
Congenital cardiac abnormality 5 (1%) 218 (6.6%) <0.001 
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Non-congenital valve disease 252 (48.8%) 1431 (43.3%) 0.018 
Median age-adjusted Charlson score 
(IQR) 
5 (4-7) 4 (3-6) <0.001 
Type of endocarditis    
Native 324 (62.7%) 2007 (60.7%) 0.355 
Prosthetic* 185 (35.8%) 955 (28.9%) 0.002 
PCM/DF
+
 8 (1.5%) 346 (10.5%) <0.001 
Valve involvement
+
    
Aortic 332 (64.3%) 1545 (46.7%) <0.001 
Mitral 226 (43.8%) 1416 (42.8%) 0.672 
Tricuspid 15 (2.9%) 186 (5.6%) 0.001 
Pulmonary 0 51 (1.5%) <0.001 
Diagnosis of endocarditis according to 
modified Duke criteria 
  0.029 
Definite 431 (83.5%) 2626 (79.4%)  
Possible 85 (16.5%) 682 (20.6%)  
Median time of symptoms duration 
until admission in non-nosocomial 
cases, days (IQR) 
6.5 (1.3-22.8) 6.5 (2-18) 0.549 
Source     
Oral 8 (1.6%) 220 (6.7%) <0.001 
Respiratory 2 (0.4%) 40 (1.2%) 0.096 
Genitourinary 92 (17.8%) 106 (3.2%) <0.001 
Gastrointestinal 82 (15.9%) 172 (5.2%) <0.001 
Vascular 62 (12%) 637 (19.3%) <0.001 
Cutaneous 10 (1.9%) 260 (7.9%) <0.001 
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Other 19 (3.8%) 202 (6.3%) 0.031 
Unknown 262 (50.8%) 1708 (51.6%) 0.734 
Etiology   NA 
Enterococci 
- E. faecalis 
- E. faecium 




















Viridans group streptococci - 616 (18.6%)  
Coagulase-negative staphylococci - 664 (20.1%)  
Bovis group streptococci - 244 (7.4%)  
Other streptococci - 193 (5.8%)  
Other - 711 (21.5%)
×
  
Acquisition    
Community 282 (54.7%) 1953 (59%) 0.062 
Health-care associated 
- Nosocomial 










Unknown 15 (2.9%) 116 (3.5%) 0.486 
Clinical complications    
New onset or worsening heart failure 









- NYHA II 
- NYHA III 
- NYHA IV 
35 (15.1%) 
95 (40.9%) 







Persistent bacteremia 69 (13.4%) 378 (11.4%) 0.223 
CNS emboli 
- Hemorrhagic 
- Extensive (>2cm) 













Other major emboli 95 (18.4%) 687 (20.8%) 0.202 
Pulmonary emboli 6 (1.2%) 183 (5.5%) <0.001 
Vertebral osteomyelitis 18 (3.5%) 97 (2.9%) 0.479 
Non-vertebral osteomyelitis 6 (1.2%) 52 (1.6%) 0.536 
Renal abscess 14 (2.7%) 87 (2.6%) 0.914 
Splenic abscess 66 (12.8%) 310 (9.4%) 0.028 
Heart conduction abnormality 39 (7.6%) 297 (9%) 0.262 
Acute renal failure 191 (37%) 1177 (35.6%) 0.530 
Septic shock 37 (7.2%) 432 (13.1%) <0.001 
Echocardiographic findings    
TEE performed 391 (75.8%) 2583 (78.1%) 0.253 
Median ejection fraction (IQR) 60% (55-65) 60% (55-65) 0.536 
Median vegetation size in mm (IQR)  8 (3-14) 8 (3-14) 0.088 
Moderate-severe aortic regurgitation 193 (37.4%) 882 (26.7%) <0.001 
Moderate-severe mitral regurgitation 197 (38.2%) 1111 (33.6%) 0.048 
Perivalvular abscess 62 (12%) 514 (15.5%) 0.024 
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Intracardiac fistula 4 (0.8%) 86 (2.6%) <0.001 
Pseudoaneurysm 18 (3.5%) 183 (5.5%) 0.023 
Leaflet perforation/rupture 70 (13.6%) 436 (13.2%) 0.082 
Treatment characteristics    
Antibiotics properly indicated 493 (95.5%) 3168 (95.8%) 0.817 
Median length of antibiotic treatment, 
days (IQR) 
42 (30-46) 36 (24-44) <0.001 
Cardiac surgery 
- Indicated 
- Operated during admission 














Outcomes     
In-hospital mortality 123 (23.8%) 892 (27%) 0.123 
Mortality at 1-year 159 (30.8%) 1100 (33.3%) 0.266 
Relapses 18 (3.5%) 57 (1.7%) 0.035 
HIV: Human immunodeficiency syndrome; IQR: Interquartile range; MSSA: methicillin-438 
susceptible S. aureus; MRSA: methicillin-resistant S. aureus; NA: not analyzed; PCM/DF: 439 
pacemakers/defibrillators  440 
* 
There were 17 cases of endocarditis over TAVI, 3 of them occurring in the EE group and 14 441 
in the NEE group (0.5% vs. 0.4%, P=0.802). 442 
+
Only episodes in which only PCM/DF are affected are included in this group. Episodes have 443 
been classified as native or prosthetic valve where a concomitant valve involvement exists. 444 
The sum does not equal 100% because episodes with multivalve involvement are also 445 
counted.  446 
±
 In 9 cases there was not identification at the species level (Enterococcus spp.), whereas the 447 
3 remaining cases corresponded to one case of E. durans, E. avium and E. gallinarum each.  448 
×
Negative culture: 342 (48.1%); Gram negative bacilli: 163 (22.9%); Polymicrobial: 69 449 
(9.7%); Candida spp: 64 (9.0%); Anaerobic bacteria: 39 (5.5%); Other fungi: 11 (1.5%); 450 






Table 2. Comparison of Health-Care acquired vs. Community-acquired Enterococcal 453 
Endocarditis. 454 











Enterococcal species    0.342 
E. faecalis 256 (90.8%) 153 (91.1%) 47 (92.2%)  
E. faecium 17 (6%) 15 (8.9%) 4 (7.8%)  
Other 9 (3.2%)* 0 0  
Median age, years (IQR)  73 (64-80) 73 (64-78) 71 (62-79) 0.332 




Diabetes mellitus 97 (34.4%) 
46 (27.3%) 17 (33.3%) 
0.296 
Chronic lung disease 73 (25.9%) 
49 (29.1%) 
12 (23,5) 0.700 
Ischemic cardiomyopathy 78 (27.7%) 56 (33.3%) 12 (23.5%) 0.285 
Congestive heart failure 101 (35.8%) 74 (44%) 19 (37.2%) 0.221 
Moderate/severe liver disease 8 (2.8%) 7 (4.2%) 8 (15.7%) 0.022 
Moderate/severe chronic renal failure 43 (15.2%) 37 (22%) 12 (23.5%) 0.120 
Hemodialysis 4 (1.4%) 11 (6.5%) 8 (15.6%) <0.001 
Neoplasm 49 (17.4%) 28 (16.6%) 13 (25.4%) 0.329 
Transplantation 2 (0.7%) 6 (3.6%) 1 (2%) 0.806 
Immunosuppressant therapy 15 (5.3%) 18 (10.7%) 4 (7.8%) 0.105 
IV drug use 5 (1.8%) 0 0 0.024 
HIV 4 (1.4%) 0 0 0.045 
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Previous IE 28 (9.9%) 24 (14.2%) 10 (19.6%) 0.101 
Congenital cardiac abnormality 4 (1.4%) 2 (1.2%) 1 (2%) 0.918 
Non-congenital valve disease 134 (47.5%) 89 (52.9%) 23 (45%) 0.445 
Median age-adjusted Charlson score 
(IQR) 
5 (4-7) 
5 (4-7) 6 (4-8) 
0.425 
Type of endocarditis     
Native 192 (68.1%) 87 (51.7%) 37 (72.5%) <0.001 
Prosthetic 86 (30.5%) 79 (47%) 13 (25.4%) <0.001 






Aortic 179 (63.5%) 105 (62.5%) 37 (72.5%) 0.403 
Mitral 122 (43.3%) 75 (44.6%) 24 (47%) 0.868 
Tricuspid 10 (3.5%) 4 (2.4%) 1 (2%) 0.398 
Pulmonary 0 0 0 1.000 
Clinical complications  
 
  
New onset or worsening heart failure 126 (44.7%) 78 (46.7%) 23 (45.1%) 0.849 
Persistent bacteremia 36 (12.8%) 23 (13.7%) 8 (15.6%) 0.652 
CNS emboli 43 (15.2%) 30 (17.8%) 10 (19.6%) 0.372 
Other major emboli 57 (20.2%) 28 (16.7%) 6 (11.8%) 0.220 
Pulmonary emboli 2 (0.7%) 4 (2.3%) 0 0.280 
Vertebral osteomyelitis 9 (3.2%) 7 (4.1%) 2 (3.9%) 0.779 
Non-vertebral osteomyelitis 5 (1.8%) 0 1 (1.9%) 0.152 
Renal abscess 8 (2.8%) 0 0 0.695 
Splenic abscess 40 (14.2%) 6 (3.5%) 3 (5.8%) <0.001 
Heart conduction abnormality 22 (7.8%) 12 (7.1%) 3 (5.8%) 0.880 
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Acute renal failure 112 (39.7%) 51 (30.3%) 19 (37.2%) 0.134 
Septic shock 19 (6.7%) 14 (8.3%) 3 (5.8%) 0.761 
Echocardiographic findings   
 
  
TEE performed 206 (73%) 134 (79.8%) 40 (78.4%) 0.093 
Median ejection fraction (%, IQR) 60 (55-65) 60 (50-65) 60 (50-68) 0.465 
Median vegetation size (mm, IQR) 8 (3-15) 10 (7-19) 10.5 (8-13) 0.729 
Moderate-severe aortic regurgitation 107 (37.9%) 54 (32.1%) 24 (47%) 0.133 
Moderate-severe mitral regurgitation 119 (42.2%) 49 (29.1%) 25 (49%) 0.006 
Perivalvular abscess 23 (8.2%) 28 (16.6%) 9 (17.6%) 0.011 
Intracardiac fistula 2 (0.7%) 2 (1.2%) 0 0.235 
Pseudoaneurysm 5 (1.8%) 6 (3.6%) 5 (9.8%) 0.010 
Leaflet perforation/rupture 44 (15.6%) 19 (11.3%) 6 (11.7%) 0.163 
Treatment characteristics     
Median length of antibiotic treatment, 
days (IQR) 
42 (29-46) 
42 (33-47) 42 (28-46) 
0.317 
Cardiac surgery 121 (42.9%) 57 (33.9%) 23 (45.1%) 0.127 
Outcomes     
In-hospital mortality 60 (21.3%) 45 (25.5%) 16 (31.3%) 0.186 
One-year mortality 79 (28%) 53 (31.5%) 22 (43.1%) 0.094 
Relapses
±
 10 (3.5%) 3 (1.7%) 4 (7.8%) 0.109 
*
 8 cases due to Enterococcus spp. and 1 case of E. durans IE 455 
± 
One case of relapse among EE was not included because it had an unknown source of 456 




Table 3. Comparison of E. faecalis vs. non-E. faecalis Enterococcal Endocarditis 459 
   E. faecalis IE 
(N=468) 
Non-E. faecalis IE 
(N=48) 
P 
Median age, years (IQR)  73 (64.5-79) 68.5 (59.5-76) 0.080 
Male sex (%)  325 (69.4%) 32 (66.7%) 0.697 
Comorbidities    
Diabetes mellitus 151 (32.3%) 17 (35.4%) 0.663 
Chronic lung disease 130 (27.8%) 9 (18.8%) 0.133 
Ischemic cardiomyopathy 140 (29.9%) 12 (25%) 0.457 
Congestive heart failure 187 (40%) 10 (20.8%) 0.002 
Moderate/severe liver disease 20 (4.3%) 4 (8.3%) 0.322 
Moderate/severe chronic renal failure 88 (18.8%) 6 (12.5%) 0.217 
Hemodialysis 24 (5.1%) 0 <0.001 
Neoplasm 81 (17.3%) 13 (27.1%) 0.142 
Transplantation 8 (1.7%) 1 (2.1%) 0.862 
Immunosuppressant therapy 33 (7.1%) 5 (10.4%) 0.461 
IV drug use 4 (0.9%) 1 (2.1%) 0.560 
HIV 3 (0.6%) 1 (2.1%) 0.491 
Previous IE 57 (12.2%) 6 (12.5%) 0.949 
Congenital cardiac abnormality 6 (1.3%) 1 (2.1%) 0.706 
Non-congenital valve disease 229 (48.9%) 23 (47.9%) 0.893 
Median age-adjusted Charlson score (IQR) 5 (4-7) 5 (3-7) 0.227 
Type of endocarditis    
Native 287 (61.3%) 37 (77.1%) 0.015 
Prosthetic 174 (37.2%) 11 (22.9%) 0.028 





    
Aortic 302 (64.5%) 30 (62.5%) 0.782 
Mitral 203 (43.4%) 23 (47.9%) 0.549 
Tricuspid 14 (3%) 1 (2.1%) 0.681 
Pulmonary 0 0 1.000 
Acquisition    
Community 256 (54.7%) 26 (54.2%) 0.944 
Health-care associated 
- Nosocomial 










Unknown 15 (3.2%) 0 0.124 
Clinical complications     
New onset or worsening heart failure 214 (45.7%) 18 (37.5%) 0.264 
Persistent bacteremia 61 (13%) 8 (16.7) 0.517 
CNS emboli 75 (16%) 11 (22.9%) 0.274 
Other major emboli 85 (18.2%) 10 (20.8%) 0.663 
Pulmonary emboli 4 (0.9%) 2 (4.2%) 0.256 
Vertebral osteomyelitis  17 (3.6%) 1 (2.1%) 0.577 
Non-vertebral osteomyelitis  6 (1.3%) 0 0.358 
Renal abscess 12 (2.6%) 2 (4.2%) 0.590 
Splenic abscess 60 (12.8%) 6 (12.5%) 0.949 
Heart conduction abnormality 36 (7.7%) 3 (6.3%) 0.697 
Acute renal failure 172 (36.8%) 19 (39.6%) 0.702 
Septic shock 31 (6.6%) 6 (12.5%) 0.232 
Echocardiographic findings    
TEE performed 358 (76.5%) 33 (68.8%) 0.267 
Median ejection fraction (IQR) 60 (55-66) 60 (55-65) 0.805 
29 
 
Median vegetation size, mm (IQR) 8 (3-14) 6 (3-8) 0.110 
Moderate-severe aortic regurgitation 179 (38.2%) 14 (29.2%) 0.191 
Moderate-severe mitral regurgitation 183 (39.1%) 14 (209.2%) 0.153 
Paravalvular abscess 60 (12.8%) 2 (4.2%) 0.008 
Intracardiac fistula 3 (0.6%) 1 (2.1%) 0.491 
Pseudoaneurysm 16 (3.4%) 2 (4.2%) 0.803 
Leaflet perforation/rupture 63 (13.5%) 7 (14.6%) 0.585 
Treatment characteristics    
Median length of antibiotic treatment, 
days (IQR)  
42 (30-46) 42 (28-44) 0.389 
Cardiac surgery 192 (41%) 18 (37.5%) 0.632 
Initial antibiotic treatment 
- Double beta-lactam combination 
















Outcomes    
In-hospital mortality 109 (23.3%) 14 (29.2%) 0.391 
Mortality at 1-year 144 (30.8%) 15 (31.3%) 0.945 
Relapses 16 (3.4%) 2 (4.2%) 0.803 
± Vancomycin plus aminoglycoside: 11 (20.4%); Vancomycin plus other: 8 (14.8%); 460 
Daptomycin: 7 (13%); Daptomycin plus beta-lactam: 5 (9.3%); Daptomycin plus fosfomycin: 461 
1 (1.8%); Beta-lactam alone: 7 (13%); Beta-lactam plus quinolone: 4 (7.4%); Linezolid: 2 462 




Table 4. Analysis of Risk Factors for In-Hospital Mortality, One-year Mortality and Relapses for 516 cases of Enterococcal 465 
Endocarditis. 466 
   One-Year Mortality Relapses 
   Univariate Multivariate Univariate Multivariate 
   HR (95%CI) P HR (95%CI) P HR (95%CI) P HR (95%CI) P 
E. faecalis 0.99 (0.58, 1.68) 0.970   






N.A.    
Male sex  0.94 (0.67, 1.31) 0.722 
  
0.44 (0.16, 1.17) 0.103 0.50 (0.19, 1.36) 0.174 
Age (years)  1.00 (0.99, 1.01) 0.534 
  
1.02 (0.98, 1.07) 0.322   
Diabetes mellitus 1.56 (1.14, 2.14) 0.006 1.00 (0.63, 1.62) 0.972 
0.69 (0.22, 2.14) 0.524   
Congestive heart 
failure 
1.10 (0.80, 1.51) 0.561 
  
0.98 (0.36, 2.70) 0.976   
Moderate-severe 
chronic renal failure 
1.97 (1.40, 2.79) <0.001 
  
1.05 (0.30, 3.67) 0.943   
Moderate-severe liver 
disease  
2.58 (2.52, 4.40) <0.001 2.62 (1.31, 5.24) 0.007 
2.95 (0.67, 12.96) 0.152 2.03 (0.45, 9.16) 0.351 
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Previous IE 0.53 (0.30, 0.96) 0.041 0.42 (0.21, 0.84) 0.012 2.45 (0.79, 7.59) 0.124   
Age-adjusted 
Charlson score  
1.16 (1.10, 1.23) <0.001 
1.12 (1.01, 1.24) 0.010 
0.93 (0.76, 1.14) 0.497   
Community 
acquisition  
0.79 (0.58, 1.08) 0.154 
  
1.17 (0.42, 3.29) 0.765   
Prosthetic IE 0.78 (0.56, 1.09) 0.158 
  
1.82 (0.68, 4.85) 0.232   
Urinary source 1.31 (0.89, 1.91) 0.172   
0.65 (0.15, 2.85) 0.576   
Aortic valve IE  1.08 (0.78, 1.50) 0.623 
  
0.42 (0.16, 1.14) 0.094 0.42 (0.16, 1.15) 0.095 
Mitral valve IE 1.07 (0.79, 1.48) 0.602   
2.15 (0.78, 5.92) 0.133 1.67 (0.49, 5.78) 0.412 
Paravalvular 
complications*  
1.52 (1.09, 2.12) 0.014 
1.87 (1.22, 2.87) 0.040 
0.19 (0.03, 1.43) 0.115 0.22 (0.03, 1.73) 0.153 
Vegetation size ≥ 
10mm 
0.79 (0.46, 1.37) 0.414 
  
0.96 (0.16, 5.72) 0.961   
New onset heart 
failure  
2.37 (1.72, 3.27) <0.001 
2.42 (1.53, 3.83) <0.001 
0.94 (0.35, 2.52) 0.904   
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Persistent bacteremia  1.37 (0.90, 2.07) 0.143 
  
3.99 (1.45, 10.98) 0.007 4.03 (1.43, 11.33) 0.008 
CNS emboli  1.23 (0.83, 1.83) 0.313 
  
1.12 (0.32, 3.94) 0.852   
Other emboli  1.05 (0.71, 1.57) 0.787 
  
0.99 (0.28, 3.48) 0.993   
New heart conduction 
abnormality  
1.58 (0.94, 2.66) 0.082 
  
N.A.    
Acute renal failure  1.86 (1.36, 2.54) <0.001 
1.30 (0.84, 2.00) 0.241 
1.31 (0.49, 3.52) 0.589   
Septic shock  3.09 (1.99, 4.77 <0.001 1.76 (1.04, 2.99) 0.033 
N.A.    
Inappropriate initial 
antibiotics  
1.71 (0.90, 3.25) 0.102 
  
N.A.    
Cardiac surgery  0.62 (0.45, 0.87) 0.006 0.88 (0.54, 1.43) 0.613 
0.33 (0.09, 1.15) 0.083 0.48 (0.13, 1.71) 0.253 
Logistic EuroSCORE  1.02 (1.01, 1.03 <0.001 
1.02 (1.01, 1.03) 0.002 
1.00 (0.98, 1.03) 0.923   
* Paravalvular complications include at least one of the following: periannular abscess, pseudoaneurysm, fistula, or leaflet perforation/rupture. 467 
N.A.= Non-assessed due to low number of events468 
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Central Illustration. Mortality and relapses in enterococcal endocarditis vs. non-469 
enterococcal endocarditis. (a) Kaplan-Meier curve for mortality at one year; (b) Kaplan-Meier 470 
curve for relapses over time. 471 













 * Shown in other large series 483 
 484 
Clinical areas and patient features in which enterococcal endocarditis is of 
special relevance:  
- Elderly patients 
- TAVI* 
- Prosthetic valve endocarditis 
- Degenerative left-sided valve disease 
- Aortic involvement 
- Chronic lung disease 
- Chronic heart failure 
- Hemodialysis* 

